Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
about
Spotlight on grazoprevir-elbasvir once-daily combination and its potential in the treatment of hepatitis CAntiviral Therapy in Patients with Viral Hepatitis and Hepatocellular Carcinoma: Indications and PrognosisNAFLD and NASH in HCV Infection: Prevalence and Significance in Hepatic and Extrahepatic ManifestationsSystemic manifestations of hepatitis C infectionInterferon-Free Treatments for Chronic Hepatitis C Genotype 1 InfectionRecent advances in managing chronic HCV infection: focus on therapy in patients with severe liver diseaseHepatitis C virus: A time for decisions. Who should be treated and when?Treatment strategies for chronic hepatitis C prior to and following liver transplantationImaging Based Methods of Liver Fibrosis Assessment in Viral Hepatitis: A Practical ApproachSignificance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinomaChronic Hepatitis C: An Overview of Evidence on Epidemiology and Management from a Brazilian Perspective.Chronic hepatitis C: This and the new era of treatmentHepatitis C genotype 4: The past, present, and futureStrategies for treating chronic HCV infection in patients with cirrhosis: latest evidence and clinical outcomesThe New Era of Interferon-Free Treatment of Chronic Hepatitis CHepatocellular Carcinoma in Patients with a Sustained Response to Anti-Hepatitis C TherapyHepatitis C cirrhosis: New perspectives for diagnosis and treatmentTreatment of hepatitis C in liver transplant patients: interferon out, direct antiviral combos inReview article: HCV genotype 3 – the new treatment challengeEmerging therapies for the treatment of hepatitis CHIV/HCV Antiviral Drug Interactions in the Era of Direct-acting AntiviralsHepatitis C virus (HCV) genotypes distribution: an epidemiological up-date in EuropeInsights for hepatitis C virus related hepatocellular carcinoma genetic biomarkers: Early diagnosis and therapeutic interventionManagement of hepatitis C infection before and after liver transplantationHepatitis C.Interferon-free combination therapies for the treatment of hepatitis C: current insightsBenefit of Treatment Individualization in Patients with Chronic Hepatitis C Receiving Peginterferon Alfa-2a and Ribavirin in a Large Noninterventional Cohort StudyWill Sofosbuvir/Ledipasvir (Harvoni) Be Cost-Effective and Affordable for Chinese Patients Infected with Hepatitis C Virus? An Economic Analysis Using Real-World DataNatural Polymorphisms Conferring Resistance to HCV Protease and Polymerase Inhibitors in Treatment-Naïve HIV/HCV Co-Infected Patients in ChinaOrigin of hepatitis C virus genotype 3 in Africa as estimated through an evolutionary analysis of the full-length genomes of nine subtypes, including the newly sequenced 3d and 3eFuture of liver disease in the era of direct acting antivirals for the treatment of hepatitis CHepatitis C virus infection.Global epidemiology and burden of HCV infection and HCV-related disease.Reinventing HCV Treatment: Past and Future Perspectives.Limiting the access to direct-acting antivirals against HCV: an ethical dilemma.Comparison of hepatocellular carcinoma in Eastern versus Western populations.HIV, Aging, and Viral Coinfections: Taking the Long View.APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing.The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma.Virologic Cure of Hepatitis C: Impact on Hepatic Fibrosis and Patient Outcomes.
P2860
Q26740233-FB95F8EC-C85F-4B5B-9BBD-353881BF4F69Q26740313-5B90F0E7-4D90-42EA-97E9-87C5E5B18ED1Q26745576-31DF4E3D-ED7F-49BF-9FB4-DF15405D249CQ26746040-DBC19948-A931-4C73-915E-662FFAAD8496Q26746563-E3FB0B0F-8EFE-4EAE-BE59-39B26F80E79DQ26752433-8F76ED4B-1CF0-40CD-98B7-EC68D6231777Q26768274-AAA5A42A-B485-4E1B-B643-567ADA3E13E2Q26771244-90A808C9-9521-4EDC-ADBD-ACE07676CA26Q26771433-381EE42C-8CEC-49DE-8B84-96FEFDFCD05EQ26773251-DD4D93EF-E936-404B-835B-6B7F6918E703Q26773585-1829E9BC-7543-4CBE-A730-90F3CFFF9E29Q26775011-7E4BAB9C-65B4-40CB-B0B6-9778D76F1020Q26775815-C2443FEF-EEE1-4D1E-B12C-1FDC541FDBFDQ26777086-0AE8AB7C-78E1-4511-A457-4D7B7D435E30Q26777716-085EDD36-68B1-4322-8681-D3713211BCF6Q26795750-E1FABF86-F156-4873-A1AB-EA15009FA3CFQ26799924-FFAB95EB-A951-432E-92A1-0EC086C86D85Q26820811-38581EC8-DE2A-47EF-B758-9411127FBD62Q26864571-026459FB-BF60-4E23-B00F-BDB4FFE64A1AQ27003319-A5426529-DEE5-476D-A1BA-13EA35A9FEC8Q28073489-449544AB-BD9A-4D01-9406-1986A5435CDAQ28079580-BE58EB77-375F-405A-8DC7-2F3678BFA79DQ28080281-D71BF123-7B4C-430C-A5C8-0CA1BC187009Q28081250-B0A38415-4B53-4329-8558-6A81BAA9C94BQ28084654-96AE79AB-3A70-4A71-9D65-B9DA2530FFD0Q28087400-214EF7B6-6483-4BAB-B6F7-1568E291F4CBQ28546936-930588B6-A5E3-4B34-BD8F-0384773F5D80Q28550101-ADF4C731-C1E3-4237-975B-9075968D4E2DQ28552134-D285FADC-5954-4C71-988D-5E8DE72F0475Q28655567-98F9F911-C2DB-45C8-BBC4-80C357070F9BQ30235178-D0BB1C0A-2F4C-4B19-BFED-9D5D5DCE52FFQ30235491-3D0B0EEA-3DDC-4179-A289-8303521C01ADQ30240220-B13EAC3E-C55D-4BBE-8D85-09D052EE824CQ30241881-CA681BDC-554E-47DA-ACB3-D145DD1714A8Q30244361-ADDA208B-5F34-4B0E-805B-02D89A503990Q30245396-9E9C52FB-FEBA-4BC9-9D64-4E4493A81A69Q30245486-AB1ABE5A-B425-4F3A-A95D-C2A3C292AFE5Q30250088-F5A19A69-B267-4DE2-902D-902752F0E9BFQ30250096-A4E0FC3D-985E-4EED-B929-2F67ACA851FDQ30250322-D6184438-F67E-4A90-BDF6-1EAA116558E9
P2860
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Association between sustained ...... and advanced hepatic fibrosis.
@en
Association between sustained ...... and advanced hepatic fibrosis.
@nl
type
label
Association between sustained ...... and advanced hepatic fibrosis.
@en
Association between sustained ...... and advanced hepatic fibrosis.
@nl
prefLabel
Association between sustained ...... and advanced hepatic fibrosis.
@en
Association between sustained ...... and advanced hepatic fibrosis.
@nl
P2093
P356
P1476
Association between sustained ...... and advanced hepatic fibrosis.
@en
P2093
Adriaan J van der Meer
Andres Duarte-Rojo
Bart J Veldt
E Jenny Heathcote
Frank Lammert
Harry L A Janssen
Heiner Wedemeyer
Jean-François Dufour
Jordan J Feld
Lorenz Kuske
P304
P356
10.1001/JAMA.2012.144878
P407
P577
2012-12-01T00:00:00Z